---
title: Small-molecule mediated MuRF1 Inhibition protects from Doxorubicin-induced
  Cardiac Atrophy and Contractile Dysfunction
date: '2024-10-04'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39366504/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241005190914&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'Cancer chemotherapy induces cell stress in rapidly dividing cancer cells
  to trigger their growth arrest and apoptosis. However, adverse effects related to
  cardiotoxicity underpinned by a limited regenerative potential of the heart limits
  clinical application: In particular, chemotherapy with doxorubicin (DOXO) causes
  acute heart injury that can transition to persisting cardiomyopathy (DOXO-CM). Here,
  we tested if MuRF1 inhibition ("MuRFi") was able to attenuate DOXO-CM. To mimic
  ...'
disable_comments: true
---
Cancer chemotherapy induces cell stress in rapidly dividing cancer cells to trigger their growth arrest and apoptosis. However, adverse effects related to cardiotoxicity underpinned by a limited regenerative potential of the heart limits clinical application: In particular, chemotherapy with doxorubicin (DOXO) causes acute heart injury that can transition to persisting cardiomyopathy (DOXO-CM). Here, we tested if MuRF1 inhibition ("MuRFi") was able to attenuate DOXO-CM. To mimic ...